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Purpose: To investigate the immediate and long-term outcomes of Ahmed glaucoma valve (AGV) implantation 
with silicone tube ligation and removable external stents.
Methods: This retrospective non-comparative study investigated the outcomes of AGV implantation with silicone 
tube ligation and removable external stents in 95 eyes (90 patients) with at least 12 months of postoperative 
follow-up. Qualified success was defined as an intraocular pressure (IOP) of ≤21 mmHg and ≥6 mmHg 
regardless of anti-glaucoma medication. Those who required additional glaucoma surgery, implant removal or 
who had phthisis bulbi were considered failures. Hypotony was defined as an IOP of <6 mmHg.
Results: Mean IOP reduced from 37.1±9.7 mmHg preoperatively to 15.2±5.6 mmHg at 12 months postoperatively 
(p<0.001). Qualified success was achieved in 84.2% at 1 year. Hypotony with an IOP of <6 mmHg was seen in 
8.4% and an IOP of <5 mmHg in 3.2% on the first postoperative day. No case of hypotony required surgical 
intervention. Suprachoroidal hemorrhage did not occur in this study. When stents were removed on the first post-
operative day because of an insufficient IOP decrease, the mean IOP decreased significantly from 42.0 mmHg to 
14.1 mmHg (p<0.001) after 1 hour. The most common complication was hyphema, which occurred in 17.9%.
Conclusions: Hypotony-related early complications requiring surgical intervention were reduced by ligation and 
external stents in the tube. In addition, early postoperative high IOPs were managed by removing external stents. 
The described method can prevent postoperative hypotony after AGV implantation and showed long-term 
success rates comparable to those reported previously.
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Glaucoma drainage devices are generally used to control 
intraocular pressure (IOP) in refractory glaucoma
1 and can 
lower IOP by allowing aqueous humor to be drained to an 
extrascleral reservoir through a small-caliber tube. Earlier 
glaucoma drainage devices have low resistance to aqueous 
outflow and cause hypotony during the immediate postope-
rative period until a fibrous capsule develops around the 
extrascleral plate.
2-4
To overcome early postoperative hypotony and its attendant 
complications, valved implants have been developed, which 
are designed to restrict excessive aqueous drainage. The Ahmed 
glaucoma valve (AGV) implant (New World Medical, Inc. 
Rancho Cucamonga, LA, USA) is a valved implant that was 
approved by the United States Food and Drug Administration in 
1993.
5
The AGV implant is designed to open when the IOP is 
between 8 mmHg and 10 mmHg, and thus maintains an IOP 
of 8 mmHg or higher.
5-7 Moreover, AGV implantation showed a 
lower incidence of postoperative hypotony than non-valved 
glaucoma drainage device implantation, but the clinical problem 
of postoperative hypotony was not resolved by valved glaucoma 
drainage devices.
5,8-12 Previous in vitro tests have shown that 
valved implants may not completely close after initial perfusion 
with fluid, and that they may function as flow-restricting 
devices without demonstrable opening or closing pressures.
6,7 
Partial ligation of the AGV tube has been attempted to lower 
early postoperative hypotony and its surgical complications.
13,14
Here, we describe the use of a ligated silicone tube with 
external stents in AGV implant surgery. The tube ligation 
was considered to restrict flow from the anterior chamber. 
External stents were added to be easily removed in cases of 
high IOP during the early postoperative period before the 
ligated suture was absorbed. In this study we aimed to in-
vestigate the immediate and long-term outcomes, in terms of 
IOP and complications, in AGV implantation using tube ligation 
and external stents.JJ Lee, et al. AHMED VALVE WITH TUBE LIGATION AND STENTS
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Fig. 1. Ahmed glaucoma valve implant surgery with ligation of silicone tube and external stents. (A) A limbus-based scleral flap was created 
with a Beaver knife. (B) The AGV plate was placed in the sub-Tenon’s space in the supero-temporal quadrant. (C) The silicone tube and 3 
strands of 8-0 Nylon were ligated with 8-0 Vicryl, and the ligature was tightened until the internal lumen of the tube collapsed. (D) The lengths 
of the exposed 8-0 Nylon strands were kept to about 5 mm to minimize corneal irritation.
Materials and Methods
A retrospective chart review was conducted on consecutive 
patients who underwent AGV implantation by a single surgeon 
(K.H.P.) at Seoul National University Hospital from January, 
2001 to July, 2004. This study was approved by the hospital 
Institutional Review Board as a retrospective chart review 
study which does not require informed consent from the 
patients. All 95 eyes of 90 patients with a minimum of 12 
months of follow-up were included. The following information 
was gathered from the charts: age, gender, race, eye laterality, 
glaucoma diagnosis, previous operation history, visual acuity, 
IOP, number of antiglaucoma medications, and postoperative 
complications.
After administering retrobulbar and facial nerve blocks, 
the affected eye was prepared with povidone-iodine and draped. 
A 6-0 black silk suture was placed through the midstromal 
cornea at the 12 o’clock position and used for traction. A 
fornix-based conjunctival flap was then created between two 
adjacent recti (superotemporal or nasal), the recti were identi-
fied, but not isolated. The AGV (model S2) was then irrigated 
with a balanced salt solution to prime the valve mechanism. 
A limbus-based scleral flap was created with a rectangle of 
4×4 mm. The plate was placed and fixed to the sclera with 
8-0 Nylon sutures 8 to 9 mm posterior to the limbus. As an 
external stent, 3 strands of 8-0 Nylon were put just beside the 
silicone tube and the ligation of both tube and stent was done 
with 8-0 Vicryl. The ligature was tightened until the internal 
lumen of the silicone tube collapsed (Fig. 1). The tube was 
then positioned over the cornea to measure the required length 
so as not to cross the pupil margin, and its tip was trimmed so 
that the bevel on the tip faced the corneal endothelial surface. 
The anterior chamber was entered through the limbus under 
the scleral flap with a 23-gauge needle. The AGV tube was 
then placed into the anterior chamber parallel to the iris plane 
through the needle track. The scleral flap was then sutured to 
cover the AGV tube. The conjunctiva and Tenon’s capsule 
were closed with 8-0 Vicryl sutures. No anti-metabolites were 
used intra- or postoperatively. The external stents consisting 
of 3 strands of 8-0 Nylon were exposed through the conjunctival 
wound. The exposed stents could be removed with a forceps 
during slit lamp examination between 1 day and 1 month Korean J Ophthalmol Vol.23, No.2, 2009
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Table 1. Patient characteristics
Characteristics Value
Number of eyes/patients 95/90
Age (mean±standard deviation) (years) 54±15
Gender
Female 28
Male 62
Diagnosis (eyes)
Neovascular glaucoma 50 (52.6%)
Secondary glaucoma after vitrectomy 16 (16.8%)
Uveitic glaucoma 9 (9.5%)
Pseudophakic glaucoma 9 (9.5%)
Congenital glaucoma 3 (3.2%)
Primary open angle glaucoma 2 (2.1%)
Miscellaneous 6 (6.3%)
Previous glaucoma surgery (eyes)
None 81 (85.3%)
One 11 (11.6%)
Two or more 3 (3.2%)
Table 2. Mean course of intraocular pressure and number of 
medications
IOP
(mean±SD)
No. of Medications 
(mean±SD)
Preoperative 37.1±9.7 3.2±1.0
First day   16.9±12.5 0.4±0.8
First week 14.5±8.4 0.6±0.9
Second week 20.7±8.6 1.0±1.0
First month 19.9±8.0 1.5±1.2
Second month 17.1±6.2 1.6±1.2
Sixth month 15.8±5.8 1.5±1.2
First year 15.2±5.6 1.4±1.3
IOP=intraocular pressure; SD=standard deviation.
Fig. 2. The mean intraocular pressure (mean±standard deviation) 
after Ahmed glaucoma valve implantation. The hypertensive phase 
occurred between 2 weeks and 1 month postoperatively. Paired t 
tests were used to compare the mean intraocular pressures at differ-
ent time points.
after AGV implant surgery. The lengths of the exposed 
Nylon strands were about 5 mm to prevent corneal irritation.
If the IOP did not reduce immediately after surgery, the 
stents were removed earlier, either on the first postoperative 
day or at 1 week. Stents were usually removed on the first day 
when the postoperative IOP was about 25 mmHg or greater. 
If the postoperative IOP was about 30% less than the pre-
operative IOP or less than 25 mmHg, stent removal was post-
poned until 1 week postoperatively.
We assessed surgical outcomes in terms of postoperative 
IOP and the incidence of complications. Complete success 
was defined as an IOP of ≤21 mmHg and ≥6 mmHg without 
additional glaucoma surgery and without anti-glaucoma medi-
cation. Qualified success was defined as an IOP of ≤21 mmHg 
and ≥6 mmHg regardless of the use of anti-glaucoma medi-
cation. Failure was defined as an IOP of >21 mmHg on 
maximally tolerated medication or <6 mmHg. Those who 
required additional glaucoma surgery, implant removal, or 
who had phthisis bulbi were also considered failures. Hypotony 
was defined as an IOP of <6 mmHg. The hypertensive phase 
(HP) was defined as that period when the IOP rose to >21 
mmHg during the first 3 postoperative months following an 
IOP reduction to ≤21 mmHg.
10 Resolution of the HP was 
evaluated by comparing IOPs and the number of medications 
needed between 6 to 8 months postoperatively and 1 month  
following the maximal IOP. Resolution of HP was defined as 
an IOP of ≤21 mmHg in conjunction with the following: a 
reduction of IOP by ≥3 mmHg on the same number of medi-
cations or less, or a reduction in at least one medication 
associated with an IOP change of <3 mmHg.
10
For comparisons between two normally distributed variables, 
we used paired t tests, and to compare paired non-normally 
distributed numeric variables we used the Wilcoxon signed 
rank test. Additionally, the cumulative probability of success 
was evaluated by Kaplan-Meier survival analysis during the 
follow-up period for more than 12 months postoperatively. 
IOP data are expressed as a mean and standard deviation. 
Two-tailed p values of <0.05 were considered statistically 
significant. Statistical analysis was conducted using SPSS 
for Windows (version 12.0, SPSS Inc., Chicago, IL).
Results
A total of 95 eyes (90 Korean patients) were included in 
this study. Table 1 summarizes the patient characteristics. 
The postoperative follow-up period was at least 12 months in 
each patient (mean follow-up period: 20.3 months). The most 
common indications for surgery were neovascular glaucoma 
(NVG) (52.6%) and secondary glaucoma after pars planar 
vitrectomy (16.8%). 81 eyes (85.3%) did not have any kind 
of glaucoma surgery before AGV implant surgery. These 
eyes had refractory glaucoma in which trabeculectomy with 
adjunctive anti-fibrotic therapy was expected to have a low 
chance of success in terms of IOP control.
15
The mean preoperative IOP was 37.1±9.7 mmHg, and the 
mean postoperative IOP was 16.9±12.5 mmHg on the first 
postoperative day and 15.2±5.6 mmHg at 12 months (Fig 2, JJ Lee, et al. AHMED VALVE WITH TUBE LIGATION AND STENTS
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Table 3. Comparisons of IOPs before and after stent removal
Time of stent removal Mean IOP before removal Mean IOP 1 hour after removal p value
*
First day (12 eyes) 42.0±7.9 mmHg 14.1±7.6 mmHg 0.002
First week (5 eyes) 34.8±8.9 mmHg   21.8±12.4 mmHg 0.068
* Wilcoxon signed rank test was conducted to compare mean IOPs before and after stent removal.
Table 4. Postoperative complications
Complications Early (before 3 months)
No. of eyes (%)
Late (after 3 months)
No. of eyes (%)
Hypotony 8 (8.4%) 2 (2.1%)
Shallow anterior chamber 6 (6.3%) 0
Hyphema 17 (17.9%) 0
Tube occlusion  2 (2.1%) 0
Choroidal effusion  1 (1.0%) 0
Phthisis bulbi 0 3 (3.2%)
Exotropia 0 1 (1.0%)
Exposure of plate 0 1 (1.0%)
Bullous keratopathy 0 1 (1.0%)
Corneal opacity (site of tube touch) 0 1 (1.0%)
Fig. 3. Mean numbers of anti-glaucoma medications (mean± 
standard deviation) after Ahmed glaucoma valve implantation. 
Paired t tests were conducted to compare the mean number of medi-
cations administered at different time points.
Table 2). The reduction in IOP over the first 12 months of 
follow-up was statistically significant (p<0.001). T tests for 
paired data showed a significant IOP reduction from the 
preoperative baseline at 1 day postoperatively (p<0.001), a 
significant increase from 1 week to 2 weeks PO (p<0.001), 
and from 1 week to 1 month postoperatively (p<0.001). A 
significant decrease also occurred between 1 and 2 months 
postoperatively (p<0.001).
The mean number of anti-glaucoma medications also 
significantly reduced during the initial postoperative phase 
and then gradually increased during the first postoperative 
year (Fig. 3, Table 2). The mean number of anti-glaucoma 
medications was 3.2 preoperatively, 0.6 at 1 week, 1.0 at 2 
weeks, 1.5 at 1 month, and 1.4 at 1 year postoperatively.
Hypotony with an IOP of <6 mmHg was seen in 8 eyes 
(8.4%) and an IOP of <5 mmHg was seen in 3 eyes (3.2%) on 
the first postoperative day before stent removal. The mean 
IOP of hypotonic eyes with an IOP of <6 mmHg was 4.1 
mmHg on the first postoperative day. Hypotony with an IOP 
of <6 mmHg was seen in 2 eyes (2.1%) at 1 week. All eyes 
had an IOP of ≥6 mmHg at 2 weeks postoperatively.
An inadequate IOP decrease (IOP>21 mmHg) was detected 
in 25 eyes (26.3%) on the first postoperative day with a mean 
IOP in these eyes of 34.9 mmHg. Stent removal was performed 
in 16 eyes (16.8%) on the first day, in 5 eyes (5.3%) at 1 week, 
and 4 eyes thereafter. IOP-lowering drugs were added for 9 
eyes (9.5%) after stent removal. IOP was controlled with 
medication only in 2 eyes (2.1%), and 2 eyes (2.1%) showed 
a normal IOP spontaneously at 1 week postoperatively. IOP 
on the visit after stent removal was in the normal range, 
except in one eye. No wound leakage was observed after 
stent removal.
A record of IOP change before and 1 hour after stent 
removal was available for 17 eyes. Twelve eyes underwent 
stent removal on the first postoperative day, with a mean IOP 
before and 1 hour after stent removal of 42.0±7.9 mmHg and 
14.1±7.6 mmHg, respectively, and this IOP reduction after 
stent removal was statistically significant (Wilcoxon signed 
rank test, p=0.002). At 1 week, the mean IOP decreased from 
34.8±8.9 mmHg to 21.8±12.4 mmHg at 1 hour after stent 
removal (in 5 eyes), with borderline significance (p=0.068) 
(Table 3). The three strands of the external stents were 
removed en bloc in most cases for rapid IOP control. Serial 
stent removal was done in only two eyes. At first, one strand 
was removed on postoperative day one, and the IOP was 
measured 30 minutes after removal. The IOP was reduced 
from 45 mmHg to 39 mmHg in one eye and from 29 mmHg 
to 25 mmHg in the other eye. Due to an insufficient IOP 
decrease, additional stent removal was continued promptly. 
The IOP finally decreased to 7 mmHg (45→39→7) and 12 mmHg 
(29→25→12), respectively, after complete stent removal.
The HP was observed in 49 eyes (51.6%) based on the Korean J Ophthalmol Vol.23, No.2, 2009
90
Fig. 4. Cumulative probability of success over time, based on 
Kaplan Meier survival analysis. Cumulative probability at 12 
months was 84.2%.
Table 5. Visual acuity after AGV implant surgery
Visual acuity Before surgery No. of eyes (%) 1 year after surgery No. of eyes (%)
≥ 20/40 3 (3.2%) 8 (8.4%)
≥ 20/200 5 (5.3%) 16 (16.8%)
≥ Counting fingers 33 (34.7%) 21 (22.1%)
Hand motion 31 (32.6%) 24 (25.3%)
Light perception 7 (7.4%) 3 (3.2%)
No light perception 16 (16.8%) 23 (24.2%)
definition given above. In 25 eyes (26.3%), the occurrence of 
the HP could not be ascertained definitely due to the use of 
medications, despite an IOP of 21 mmHg or less. The HP 
appeared after an average time of 2.7±1.5 weeks. The highest 
IOP in these eyes with a HP ranged from 22 to 48 mmHg, 
with a mean of 29.8±6.9 mmHg. HP resolution occurred in 
38 of the 49 eyes (77.6%), according to the study definition. 
In most patients that experienced a HP, the IOP was controlled 
by additional medication. Needling of the bleb was done in 2 
eyes, and a second implant was required in three.
Complications occurred in 33 (34.7%) of 95 eyes after 
AGV implantation (Table 4). Eight eyes (8.4%) had more than 
one complication. Complications during the early postopera-
tive period (within 3 months of AGV surgery) were hyphema, 
postoperative hypotony, a shallow anterior chamber, tube 
occlusion, and choroidal effusion. Late hypotony, phthisis, 
exotropia, plate exposure, bullous keratopathy, and corneal 
opacity were later complications and were encountered after 
3 months postoperatively.
The most common complication was hyphema in 17 eyes 
(17.9%). 88.2% (15 eyes) of these hyphema cases occurred 
in patients with NVG. Six eyes (6.3%) showed a shallow 
anterior chamber on the first postoperative day. The mean 
IOP of these 6 eyes was 9.5 mmHg, and one eye had hypotony. 
Suprachoroidal hemorrhage did not occur. Choroidal effusion 
occurred in one eye with congenital glaucoma and an IOP of 
6 mmHg, and was treated with oral prednisolone. Tube occlu-
sion was observed in two eyes. These were caused by a blood 
clot and a vitreous strand in two pseudophakic glaucoma 
patients. A Nd:YAG laser was used on the tube occluded with 
the vitreous strand due to a high IOP.
Late hypotony occurred 6 months postoperatively and 
lasted for more than 3 months in 2 eyes (2.1%). These eyes 
had shown a normal range of IOPs before the development of 
late hypotony, without a history of early postoperative hypotony. 
Phthisis occurred in 3 eyes (3.2%). All 3 of these eyes were 
diagnosed as NVG preoperatively. At the time of AGV implan-
tation, 1 eye had had a chronic total retinal detachment with 
no treatment, and 1 eye had undergone vitrectomy because of 
total retinal detachment. The AGV was removed due to plate 
exposure in one eye, but the IOP after AGV removal was 
within the normal range with tolerable medication.
Visual acuity was within one line in 55 eyes (57.9%) but 
had worsened two lines or more in 17 eyes (17.9%) at 1 year 
after surgery. Seven eyes (7.4%) that had NVG and poor vision 
before surgery, ranging from counting fingers at 30 cm to 
light perception, lost light perception during the current study. 
In the present study, AGV implantations were performed in 
16 eyes (16.8%) with no light perception. The purpose of the 
operation in these patients was to control pain and maintain 
the eyeball by lowering the IOP (Table 5).
In this study, 15 eyes (15.8%) were considered failures. 6 
eyes (6.3%) had more than 21 mmHg with medication. An 
additional drainage device was implanted in 3 of these eyes 
(3.2%). Five of the 15 eyes (5.3%) failed because of hypotony 
and phthisis, and the implant was removed from the remaining 
eye (1.0%) due to plate exposure.
Based on our criteria for success, complete success was 
achieved in 28 eyes (29.5%), and qualified success in 80 eyes 
(84.2%) at 1 year. Kaplan-Meier survival analysis showed a 
cumulative probability of success of 84.2% after 12 months 
(Fig. 4).
Discussion
Early postoperative hypotony and its attendant complica-
tions, including choroidal detachment and suprachoroidal 
hemorrhage, still continue to present a clinical problem in 
valved glaucoma implants. The incidences of early postope-
rative hypotony in AGV implant surgery range from 8% to 
13% using an intraocular pressure definition of <5 mmHg or JJ Lee, et al. AHMED VALVE WITH TUBE LIGATION AND STENTS
91
6 mmHg.
5,8-12 In previous studies, suprachoroidal hemorrhage 
occurred in 1.7% to 4.7% of AGV implantations.
5,8-12 This 
has been explained by valve failure, leakage around the tube, 
or a decrease in aqueous production.
13,16 Of these possible 
causes of early postoperative hypotony, leakage around the 
tube is now prevented by corneal puncture using a 23-gauge 
needle.
5
Kee
13 used partial ligation of a silicone tube with 8-0 
Vicryl in AGV, to restrict aqueous humor flow.
13,14 He showed 
that the early postoperative hypotony and its surgical compli-
cations are less frequent if the AGV tube is partially ligated, 
but differences between the ligation and non-ligation groups 
were not statistically significant in his study, probably because 
of a small sample size.
13
In the previous partial ligation study, the operator ligated 
both the tube and a stent (6-0 Prolene) with 8-0 Vicryl and 
then removed the stent. In the present study, the ligation of the 
AGV silicone tubes with 8-0 Vicryl was done in combination 
with the use of 3 strands of 8-0 Nylon as external stents. We 
did not remove the stents intraoperatively (complete ligation). 
We decided when to remove the stents according to the post-
operative IOP. When IOPs failed to reduce postoperatively, 
stents were removed early to increase internal tube diameters. 
This method may have advantages compared to the previous 
partial ligation method in that IOP control is easier and more 
adjustable because the time of stent removal can be decided 
according to the postoperative state. The stents were simply 
removed with a forceps under a slit lamp because they remained 
exposed to the conjunctival surface. Moreover, stent removals 
during the immediate postoperative period were accompanied 
by rapid and sufficient IOP reductions, which suggest that 
enlargement of the tube lumen induces enhanced outflow and 
subsequent IOP reduction. The disadvantage may be irritation 
due to the external stents, however, this can be minimized by 
ensuring an adequate length of the 8-0 Nylon strands so as 
not to touch the cornea and removal within one month in 
most cases.
There were two reasons for using three strands of 8-0 
Nylon as external stents rather than one large single strand. 
One was to reduce conjunctival irritation because one thick 
suture creates a greater sense of a foreign body than three 
thinner strands. The second reason is that they were originally 
intended to allow high postoperative IOP adjustment by 
removing them one by one. During the course of the study 
they were removed en bloc in most cases for fast IOP control; 
however, in two cases where stents were serially removed, 
additional stent removal resulted in additional IOP reduction, 
suggesting the advantage of multiple thin external stents.
We have to consider the reason for the occasional lack of a 
postoperative day one IOP spike despite the complete ligation 
of the tube. One possibility is that complete ligation was not 
performed in all cases because there might have been a 
minute space open inside the lumen of the ligated tube, or 
there is a possibility that there might be a flow of aqueous 
through the space between the tube and the corneoscleral 
ostium in the early postoperative period.
As a result of ligation and external stenting, 3 eyes (3.2%) 
showed an IOP of <5 mmHg on the first postoperative day. 
All hypotonic eyes recovered to the normal range within 2 
weeks. A total of 6 eyes (6.3%) had a shallow anterior chamber 
on the first postoperative day in this study. We had no ex-
perience of flat or shallow anterior chambers that required 
surgical chamber reformation during the course of the study, 
and no suprachoroidal hemorrhage occurred. A choroidal 
effusion occurred in one eye with congenital glaucoma and 
an IOP of 6 mmHg on the first postoperative day, but this 
spontaneously regressed and did not require surgical inter-
vention.
Molteno and Dempster
14 reported a transient IOP ele-
vation following a short-lived HP after single-plate Molteno 
implant surgery. This HP has been also reported for AGV 
implantation.
4,9,10 The HP appeared approximately 4 weeks 
after surgery and lasted for at least 12 to 16 weeks. This phase 
is caused by histological changes in the bleb around an 
implant end-plate related to the formation of a layer of fibrous 
tissue in the bleb after diffuse edema and congestion disappears. 
The fibrotic capsule formed is resistant to aqueous flow, and 
thus results in an IOP elevation.
13,16,17
In the current study, it was found that the HP appeared 
after an average of 2.7±1.5 weeks in 49 eyes (51.6%), the 
occurrence of the HP could not be ascertained in 25 eyes 
(26.3%) due to the use of medications. The mean highest IOP 
in those with a HP was 29.8±6.9 mmHg. The mean IOP 
profile also started to increase between 1 and 2 weeks after a 
fall in IOP on the first postoperative day. The mean IOP peaked 
from 2 weeks to 1 month postoperatively, and then stabilized 
over the ensuing months. Although the HP occurred earlier 
than in previous studies, the incidence of a HP and the mean 
highest IOP in those that developed a HP were similar to 
those reported for conventional AGV implant surgery. Tube 
ligation and external stent placement did not affect the HP, 
except for the time of occurrence. This is believed to be 
caused by an early IOP elevation due to the tube ligation.
In this study, the mean number of anti-glaucoma medications 
was larger at 1 month postoperatively (1.5±1.2) than has been 
reported previously (0.4 to 0.82), though the mean medi-
cation number at 1 year postoperatively was similar to those 
of other studies.
9,10 An early increase in medication is also 
related to the early appearance of the HP.
The cumulative probability of success at 1 year was 84.2% 
in the present study, which compares favorably with the success 
rates reported by previous studies (70% to 87%),
8,13-16,18,19 
although some of the criteria used to measure success differ 
between studies.
Our study has the limitation that it is not a prospective, 
randomized, controlled trial. Despite its limitations, no other 
review has been conducted on the long-term follow-up data 
of a large number of patients that have undergone AGV 
implantation with tube ligation and external stents.
In conclusion, AGV implantation with tube ligation and Korean J Ophthalmol Vol.23, No.2, 2009
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external stents prevented hypotony-related early complications 
requiring surgical intervention. Moreover, the described method 
was found to result in a satisfactory IOP reduction in refractory 
glaucoma at 1 year postoperatively with a qualified success rate 
of 84.2%, comparable to those reported previously.
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